Clostridial spores for cancer therapy: Targeting solid tumour microenvironment

Journal of Toxicology

Volumn 2012, Issue , 2012, Pages

  Umer, Brittany ^a   Good, David ^b   Anné, Jozef ^c   Duan, Wei ^d   Wei, Ming Q ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; CYTOKINE; CYTOSINE DEAMINASE; DOCETAXEL; DOXORUBICIN; ENTEROTOXIN; FLUCYTOSINE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 2; LIPOSOME; MITOMYCIN C; NAVELBINE; NITROREDUCTASE; TRETAZICAR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; APOPTOSIS; BACTERIAL COLONIZATION; BACTERIAL SPORE; BACTERIAL STRAIN; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLOSTRIDIUM; CLOSTRIDIUM ACETOBUTYLICUM; CLOSTRIDIUM BEIJERINCKII; CLOSTRIDIUM DIRECTED ANTIBODY THERAPY; CLOSTRIDIUM DIRECTED ENZYME PRODRUG THERAPY; CLOSTRIDIUM NOVYI; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM SPOROGENES; COMBINED BACTERIOLYTIC THERAPY; DNA MODIFICATION; DRUG EFFECT; DRUG POTENTIATION; DRUG RELEASE; ENZYME PRODRUG THERAPY; EXTRACELLULAR MATRIX; GENETIC ENGINEERING; HUMAN; HYPOXIA; INFLAMMATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SPORE GERMINATION; TISSUE PRESSURE; TUMOR MICROENVIRONMENT; TUMOR NECROSIS;

CLOSTRIDIUM;

EID: 84863641260     PISSN: 16878191     EISSN: 16878205     Source Type: Journal    
DOI: 10.1155/2012/862764     Document Type: Review

References (52)

1. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases Nature 2000 407 6801 249 257
2. Helmlinger G., Yuan F., Dellian M., Jain R. K., Interstitial pH and pO 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation Nature Medicine 1997 3 2 177 182 (Pubitemid 27064702)
3. Pepper M. S., Ferrara N., Orci L., Montesano R., Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro Biochemical and Biophysical Research Communications 1992 189 2 824 831 (Pubitemid 23032448)
4. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E., Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity Nature Medicine 1995 1 10 1024 1028
5. Carmeliet P., VEGF as a key mediator of angiogenesis in cancer Oncology 2005 69 3 4 10 (Pubitemid 41680947)
6. Thomas K. A., Vascular endothelial growth factor, a potent and selective angiogenic agent Journal of Biological Chemistry 1996 271 2 603 606 (Pubitemid 26034900)
7. Melillo G., Targeting hypoxia cell signaling for cancer therapy Cancer and Metastasis Reviews 2007 26 2 341 352 (Pubitemid 47101663)
8. Semenza G. L., Targeting HIF-1 for cancer therapy Nature Reviews Cancer 2003 3 10 721 732 (Pubitemid 37328811)
9. Havell E. A., Fiers W., North R. J., The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity Journal of Experimental Medicine 1988 167 3 1067 1085
10. Regg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., Lejeune F. J., Evidence for the involvement of endothelial cell integrin V 3 in the disruption of the tumor vasculature induced by TNF and IFN- Nature Medicine 1998 4 4 408 414 (Pubitemid 28212755)
11. Leber T. M., Balkwill F. R., Regulation of monocyte MMP-9 production by TNF- and a tumour-derived soluble factor (MMPSF) British Journal of Cancer 1998 78 6 724 732 (Pubitemid 28418303)
12. Dalgleish A. G., Haefne B., The Link between Inflammation and Cancer: Wounds that Do Not Heal 2006 New York, NY, USA Springer
13. Beg A. A., Baltimore D., An essential role for NF- B in preventing TNF- -induced cell death Science 1996 274 5288 782 784 (Pubitemid 26398258)
14. Rojiani M. M., Wiranowska M., Rojiani A. M., Sienmann D. W., Matrix matalloproteinases and their inhibitorsfriend of foe Tumor Microenvironment 2011 New York, NY, USA Wiley-BlackWell 53 76
15. Hynes R. O., Rich A., Fibronectins Springers Series in Molecular Biology 1990 New York, NY, USA Springer 1 53
16. Menrad A., Bagley R. G., Fibronectin The Tumour Microenvironment 2010 New york, NY, USA Springer 457 476
17. Lauer J. L., Fields G. B., Bagley R. G., Collagen in cancer The Tumour Microenvironment 2010 New york, NY, USA Springer 477 507
18. Wouters B. G., Weppler S. A., Koritzinsky M., Landuyt W., Nuyts S., Theys J., Chiu R. K., Lambin P., Hypoxia as a target for combined modality treatments European Journal of Cancer 2002 38 2 240 257 (Pubitemid 34136999)
19. Martin M. D., Matrisian L. M., The other side of MMPs: protective roles in tumor progression Cancer and Metastasis Reviews 2007 26 3-4 717 724 (Pubitemid 350115119)
20. Morrison C. J., Butler G. S., Rodrguez D., Overall C. M., Matrix metalloproteinase proteomics: substrates, targets, and therapy Current Opinion in Cell Biology 2009 21 5 645 653
21. Page-McCaw A., Ewald A. J., Werb Z., Matrix metalloproteinases and the regulation of tissue remodelling Nature Reviews Molecular Cell Biology 2007 8 3 221 233
22. Hiraoka N., Allen E., Apel I. J., Gyetko M. R., Weiss S. J., Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins Cell 1998 95 3 365 377 (Pubitemid 28507325)
23. Jordan B. F., Gallez B., Siemann D. W., Non-invasive imaging of the tumor microenvironment Tumor Microenvironment 2010 New York, NY, USA Wiley-BlackWell 229 270
24. Heldin C. H., Rubin K., Pietras K., Ostman A., High interstitial fluid pressurean obstacle in cancer therapy Nature Reviews Cancer 2004 4 10 806 813 (Pubitemid 39331152)
25. Mantovani A., Allavena P., Sica A., Balkwill F., Cancer-related inflammation Nature 2008 454 7203 436 444
26. Murooka T. T., Ward S. E., Fish E. N., Chemokines and cancer Cancer Treatment and Research 2005 126 15 44
27. Tartour E., Fridman W. H., Cytokines and cancer International Reviews of Immunology 1998 16 5-6 683 704 (Pubitemid 28286190)
28. Parmiani G., Rivoltini L., Andreola G., Carrabba M., Cytokines in cancer therapy Immunology Letters 2000 74 1 41 44
29. Kizaka-Kondoh S., Inoue M., Harada H., Hiraoka M., Tumor hypoxia: a target for selective cancer therapy Cancer Science 2003 94 12 1021 1028 (Pubitemid 38035514)
30. Brown J. M., Wilson W. R., Exploiting tumour hypoxia in cancer treatment Nature Reviews Cancer 2004 4 6 437 447 (Pubitemid 38745529)
31. Mangesha A., Dubois L., Paesmans K., Wouters B., Lambin P., Theys J., Gottschalk G., Brggemann H., Clostridia in anti-tumour therapy Clostridia: Molecular Biology in the Post-Genomic Era 2009 Norwich, UK Horizon Scientific Press 213
32. Zhou J., Schmid T., Schnitzer S., Brune B., Tumor hypoxia and cancer progression Cancer Letters 2006 237 1 10 21
33. Pipiya T., Sauthoff H., Huang Y. Q., Chang B., Cheng J., Heitner S., Chen S., Rom W. N., Hay J. G., Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression Gene Therapy 2005 12 11 911 917 (Pubitemid 40852209)
34. Shen B. H., Hermiston T. W., Effect of hypoxia on Ad5 infection, transgene expression and replication Gene Therapy 2005 12 11 902 910 (Pubitemid 40852208)
35. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., Koromilas A., Wouters B. G., Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2 Molecular and Cellular Biology 2002 22 21 7405 7416
36. Lambin P., Theys J., Landuyt W., Rijken P., Van Der Kogel A., Van Der Schueren E., Hodgkiss R., Fowler J., Nuyts S., De Bruijn E., Van Mellaert L., Anné J., Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours Anaerobe 1998 4 4 183 188 (Pubitemid 28528803)
37. Minton N. P., Mauchline M. L., Lemmon M. J., Brehm J. K., Fox M., Michael N. P., Giaccia A., Brown J. M., Chemotherapeutic tumour targeting using clostridial spores FEMS Microbiology Reviews 1995 17 3 357 364
38. Patyar S., Joshi R., Byrav D. S. P., Prakash A., Medhi B., Das B. K., Bacteria in cancer therapy: a novel experimental strategy Journal of Biomedical Science 2010 17 1, article no. 21
39. Liu S. C., Minton N. P., Giaccia A. J., Brown J. M., Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis Gene Therapy 2002 9 4 291 296 (Pubitemid 34256904)
40. Liu S. C., Ahn G. O., Kioi M., Dorie M. J., Patterson A. V., Brown J. M., Optimized Clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104 Cancer Research 2008 68 19 7995 8003
41. Theys J., Nuyts S., Landuyt W., Van Mellaert L., Dillen C., Bhringer M., Drre P., Lambin P., Anné J., Stable Escherichia coli- Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha Applied and Environmental Microbiology 1999 65 10 4295 4300
42. Barbe S., Van Mellaert L., Theys J., Geukens N., Lammertyn E., Lambin P., Anné J., Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment FEMS Microbiology Letters 2005 246 1 67 73 (Pubitemid 40616285)
43. McIntosh J. K., Mule J. J., Krosnick J. A., Rosenberg S. A., Combination cytokine immunotherapy with tumor necrosis factor, interleukin 2, and -interferon and its synergistic antitumor effects in mice Cancer Research 1989 49 6 1408 1414 (Pubitemid 19088674)
44. Groot A. J., Verheesen P., Westerlaken E. J., Gort E. H., Van Der Groep P., Bovenschen N., Van Der Wall E., Van Diest P. J., Shvarts A., Identification by phage display of single-domain antibody fragments specific for the ODD domain in hypoxia-inducible factor 1alpha Laboratory Investigation 2006 86 4 345 356
45. Groot A. J., Mengesha A., Wall E. V. D., Diest P. J. V., Theys J., Vooijs M., Functional antibodies produced by oncolytic clostridia Biochemical and Biophysical Research Communications 2007 364 4 985 989 (Pubitemid 350087897)
46. Yao Q., Cao S., Li C., Mengesha A., Low P., Kong B., Dai S., Wei M., Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers Biochemical and Biophysical Research Communications 2010 398 3 413 419
47. Dang L. H., Bettegowda C., Huso D. L., Kinzler K. W., Vogelstein B., Combination bacteriolytic therapy for the treatment of experimental tumors Proceedings of the National Academy of Sciences of the United States of America 2001 98 26 15155 15160 (Pubitemid 34013985)
48. Cheong I., Huang X., Bettegowda C., Diaz L. A., Kinzler K. W., Zhou S., Vogelstein B., A bacterial protein enhances the release and efficacy of liposomal cancer drugs Science 2006 314 5803 1308 1311 (Pubitemid 44846406)
49. Theys J., Pennington O., Dubois L., Anlezark G., Vaughan T., Mengesha A., Landuyt W., Anné J., Burke P. J., Drre P., Wouters B. G., Minton N. P., Lambin P., Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo British Journal of Cancer 2006 95 9 1212 1219 (Pubitemid 44658485)
50. Fox M. E., Lemmon M. J., Mauchline M. L., Davis T. O., Giaccia A. J., Minton N. P., Brown J. M., Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia Gene Therapy 1996 3 2 173 178 (Pubitemid 26117427)
51. Barbe S., Optimization and evaluation of the clostridium-mediated transfer system of therapeutic proteins to solid tumour, Ph.D. thesis 2005 Bio-Sciences Engineering, University of Leuvin
52. Dang L. H., Bettegowda C., Agrawal N., Cheong I., Huso D., Frost P., Loganzo F., Greenberger L., Barkoczy J., Pettit G. R., Smith A. B., Gurulingappa H., Khan S., Parmigiani G., Kinzler K. W., Zhou S., Vogelstein B., Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents Cancer Biology and Therapy 2004 3 3 326 337 (Pubitemid 41357473)